BioSight
Back
CRISPR Therapeutics AG logo

CRSP

NASDAQZUG
CRISPR Therapeutics AG

CRISPR Therapeutics AG develops gene editing product candidates using CRISPR/Cas9 technology to treat human diseases. The company is in the early stages of clinical development, with only a limited number of clinical trials underway for its gene editing-based therapies. CRISPR Therapeutics has not yet achieved regulatory approval for any products and expects to incur significant operating losses for the foreseeable future while advancing its pipeline toward commercialization.

$52.34+35.35%1Y
CRSP · daily close · illustrative · 0 catalysts marked
1Y high$76.781Y low$33.16range$43.62(132%)past catalysts

Pipeline2

CTX112
Phase 2B-cell Lymphoma
Phase 2Non-Hodgkin Lymphoma
Phase 2B-cell Malignancy
Phase 2Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
Phase 2Follicular Lymphoma
Phase 2Mantle-cell Lymphoma
Phase 2Marginal Zone Lymphoma
Phase 2Large B-cell Lymphoma

Next-generation allogeneic CD19-directed CAR-T therapy (CRISPR Therapeutics) with multiple gene edits to improve persistence and reduce rejection. Phase 1/2 in B-cell malignancies and lupus.

cell-therapy
Allogeneic CD19 CAR-T (next-generation)
→ CD19
CTX320
UnknownIndication pending review

Catalyst Calendar1

H1
'26
164d ago
ReadoutCTX320
“An update is now expected in the first half of 2026, reflecting a strategic decision to incorporate emerging insights from the evolving Lp(a) landscape.”
8-K ↗

Disclaimer·BioSight aggregates publicly available data (SEC EDGAR, ClinicalTrials.gov, FDA, company press releases) and is provided as is for informational purposes only. Nothing here is investment, financial, legal, tax, or medical advice, or an offer to buy or sell any security. We make no warranty as to accuracy, completeness, or timeliness; dates and filings may contain errors or be superseded without notice; past events do not predict future outcomes. To the maximum extent permitted by law, BioSight, its operators, contributors, and affiliates disclaim all liability for any loss or damage arising from use of or reliance on this site. You are solely responsible for your own investment decisions — consult a licensed professional before acting on any information.